UBS raises Encompass Health stock price target to $165 on outlook
UBS raised its price target for Encompass Health (EHC) to $165 from $155, citing strong EBITDA performance and a positive 2027 outlook. The company expects growth from capacity expansion, VA growth, and Medicare Advantage programs. EHC reported Q3 earnings of $1.52 per share, beating estimates, with revenue at $1.61 billion. KeyBanc and Truist also raised their price targets to $150 and $156, respectively.
How this was made
The 30-second read
Why it matters
Analyst upgrades can act as catalysts, especially when tied to concrete earnings beats and expansion guidance.
Market read
Analyst target raise on EHC may prompt short‑term buying interest, supporting the stock amid a broader healthcare rally.
What to watch
Potential risks from bad‑debt and administrative challenges in the RCD expansion.
Background
UBS and other analysts upgraded Encompass Health after its Q3 earnings beat and outlined growth plans for small‑format hospitals.
Ticker impact
UBS raised its price target on Encompass Health (EHC) to $165, citing strong adjusted EBITDA and recent Q3 earnings beat.
likely upward pressure as investors price in higher valuation expectations
Analyst target increase reflects better-than-expected earnings and growth outlook, which can attract buying.
Market effects
reinforces positive outlook for the inpatient rehabilitation sector
U.S. healthcare stocks may see modest uplift
limited to U.S. equities
Counterpoint
Target raise may be premature if growth assumptions falter, risking a pull‑back.
Key entities
- companyEncompass Health Corp
U.S. provider of inpatient rehabilitation services.
- analystUBS
Raised price target to $165.
